John P. Butler
CIK 1591467 · CEO and President · last filed 2026-08-10
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$3.37M
Companies
4
Total Filings
60
Lifetime Open-Market Net
-$1.02M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| AKBA | CEO and President | 3,878,492 | $0.87 | $3.37M | -$999.1K | 37 | 2026-08-10 |
| Zynerba Pharmaceuticals, Inc. (ZYNE) Delisted | Director | 47,824 | $1.30 | $62.2K | $32.1K | 9 | 2023-10-11 |
| KERYX BIOPHARMACEUTICALS INC (KERX) Delisted | Director | 20,000 | — | — | $0 | 2 | 2017-06-20 |
| Relypsa Inc (RLYP) Delisted | Director | 2,250 | — | — | -$57.7K | 6 | 2016-09-02 |
Recent Filings · Page 4 of 6
60 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2019-06-13 | Zynerba Pharmaceuticals, Inc. (ZYNE) Delisted | Grant (A) | — | $0 | EDGAR |
| 2019-06-05 | AKBA | Exer (M) | +287,000 | $134.9K | EDGAR |
| 2019-03-05 | AKBA | Grant (A) | +239,500 | $0 | EDGAR |
| 2018-12-13 | AKBA | Tax (F) | −135,697 | -$1.21M | EDGAR |
| 2018-08-22 | Zynerba Pharmaceuticals, Inc. (ZYNE) Delisted | Buy (P) | +5,000 | $32.2K | EDGAR |
| 2018-07-12 | AKBA | Exer (M) | +100,000 | $47.0K | EDGAR |
| 2018-06-07 | Zynerba Pharmaceuticals, Inc. (ZYNE) Delisted | Grant (A) | — | $0 | EDGAR |
| 2018-04-16 | Zynerba Pharmaceuticals, Inc. (ZYNE) Delisted | Grant (A) | — | $0 | EDGAR |
| 2018-03-02 | AKBA | Grant (A) | +88,900 | $0 | EDGAR |
| 2017-06-20 | KERYX BIOPHARMACEUTICALS INC (KERX) Delisted | Grant (A) | +10,000 | $0 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.